Mark Vexelman, MD
Family Medicine · Chicago, ILNPI 1700896750
Payments from drug & device makers
Across 193 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$309
- Novo Nordisk$266
- Smith+Nephew$262
- Johnson & Johnson$241
- E.r. Squibb & Sons, L.L.C.$241
- AstraZeneca$213
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,249100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $309 |
| Novo Nordisk | 16 | $266 |
| Smith+Nephew | 15 | $262 |
| Johnson & Johnson | 13 | $241 |
| E.r. Squibb & Sons, L.L.C. | 12 | $241 |
| AstraZeneca | 14 | $213 |
| GSK | 18 | $203 |
| Amarin Pharma, Inc. | 12 | $202 |
| AbbVie(2 entities) | 14 | $183 |
| Lilly USA, LLC | 11 | $150 |
| Merck | 8 | $145 |
| Boehringer Ingelheim | 5 | $105 |
| ETS Wound Care LLC | 4 | $95 |
| Amgen | 5 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $64 |
| Novartis | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Tactile Systems Technology Inc | 1 | $43 |
| Reapplix Inc. | 2 | $34 |
| Mimedx Group, Inc. | 1 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Kerecis Limited | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Solventum Corporation | 1 | $27 |
| Astellas Pharma US Inc | 1 | $23 |
| Pacira Therapeutics, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $23 |
| Organogenesis Inc. | 1 | $22 |
| Hartmann USA, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Medline Industries LP | 1 | $17 |
| Aroa Biosurgery Incorporated | 2 | $12 |
| Next Science LLC | 1 | $7 |
How this compares
$3,263 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 597 | $322,001 |
| OzempicSemaglutide | 88 | $91,324 |
| JardianceEmpagliflozin | 108 | $75,604 |
| XareltoRivaroxaban | 96 | $66,427 |
| NuplazidPimavanserin Tartrate | 19 | $46,755 |
| JanuviaSitagliptin Phosphate | 72 | $42,254 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $35,354 |
| FarxigaDapagliflozin Propanediol | 37 | $27,465 |
| MyrbetriqMirabegron | 93 | $26,756 |
| IsentressRaltegravir Potassium | 11 | $24,422 |
| TeflaroCeftaroline Fosamil Acetate | 26 | $21,893 |
| LinzessLinaclotide | 24 | $21,091 |
| InvokanaCanagliflozin | 13 | $20,426 |
| VascepaIcosapent Ethyl | 47 | $19,943 |
| RybelsusSemaglutide | 11 | $16,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $309 | $322,001597 claims |
| Novo NordiskOzempic, Rybelsus | $266 | $108,03099 claims |
| MerckJanuvia, Isentress, Janumet, Janumet Xr, Lagevrio (Eua) | $145 | $107,016150 claims |
| Boehringer IngelheimJardiance, Tradjenta | $105 | $87,233122 claims |
| Johnson & JohnsonXarelto, Invokana | $241 | $86,853109 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $203 | $65,538105 claims |
| AbbVieTeflaro, Linzess, Namzaric, Synthroid | $183 | $61,775170 claims |
| AstraZenecaFarxiga, Brilinta | $213 | $33,02255 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $26,75693 claims |
| Lilly USA, LLCTrulicity | $150 | $15,00511 claims |
| Smith+NephewSantyl | $262 | $12,50827 claims |
| NovartisEntresto | $62 | $10,57622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chicago
- Bradley TorphyChicago$3M
- Frank PhillipsChicago$1.6M
- Ayoade AkereChicago$484K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
- Jacqueline OlivoChicago$165K
- Sameer PanjwaniChicago$136K
- Igor AltmanChicago$64K
- Juan RojasChicago$40K
- Mark SimonChicago$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.